Power Versus Temperature Controlled Ablation for Treatment of VT
NCT ID: NCT06028919
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
64 participants
INTERVENTIONAL
2022-09-26
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The majority of patients that are at risk of VT or suffer a cardiac arrest will have an Internal Cardiac Defibrillator (ICD) in situ to treat the abnormal heart rhythm. The ICD can deliver a painful shock to restore normal heart rhythm but importantly does not treat the underlying cause. Current treatment for the prevention of recurrent VT include catheter ablation (CA) or medication. Long-term results with global 12 month VT-free survival rates with CA are around 50%.
The trial is to compare 2 different types of ablation catheter that are used to cauterise small areas of unhealthy tissue within the heart that are responsible for VT: Diamond Temp (DT) and Tacticath/Tactiflex (TF). Our hypothesis is that the DT ablation catheter will provide comparable efficacy and safety for the treatment of VT as the current industry gold standard (TF).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia
NCT01182389
Therapy Cool Path Ablate VT
NCT00925522
International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease with Minimally Impaired Ejection Fraction
NCT06294028
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
NCT01557842
Ventricular Tachycardia Cohort
NCT07149701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Current treatments for VT include catheter ablation (CA), medication and having an internal cardiac defibrillator (ICD) implanted, each treatment has advantages and disadvantages. The ICD can deliver a lifesaving shock but this doesn't treat the cause of the VT and can be very painful and upsetting for the patient. Medications can reduce the amount and rate of VT but can have dangerous side effects.
CA involves small tubes being placed in the heart and small areas of unhealthy heart tissue are burnt (ablated) to stop the VT. This is the only treatment that treats the underlying cause but long-term success is about 50% after 1 year.
The investigators want to improve the success rates of VT ablation. There is a new ablation catheter called Diamond Temp which works differently to the current industry gold standard (Tacticath/Tactiflex Catheter). The investigators think the Diamond Temp catheter will be better than the Tacticath catheter but need to do this trial to prove it.
This trial will be at University Hospital Coventry and Warwickshire and University Hospitals Sussex involving patients that suffer VT, have an ICD and need an ablation. If a patient wishes to participate they will give consent and be chosen at random to receive ablation with either Diamond temp or Tacticath/Tactiflex. All other treatment will be the same as after a normal ablation procedure. Participants will be followed up at 6 months and 1 year after the procedure as well as being monitored by the ICD clinic. The study will have 54 patients and be completed in 2025.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Temperature controlled DiamondTemp (DT) ablation catheter
Intervention arm
Temperature controlled DiamondTemp (DT) ablation catheter
The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
Power controlled Tacticath/Tactiflex ablation catheter
Control arm
Tacticath/Tactiflex (TF) ablation catheter
The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Temperature controlled DiamondTemp (DT) ablation catheter
The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
Tacticath/Tactiflex (TF) ablation catheter
The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject with 1 of the following:
1. Symptomatic VT (despite optimal medical therapy), 3 or more episodes of VT within 24 h (VT storm).
2. At least 3 episodes of VT requiring anti-tachycardia pacing (ATP)
3. At least one appropriate ICD shock.
* Referred for VT ablation by Consultant Electrophysiologist
* Subject discussed at cardiac EP MDT
* Suitable candidate for intra-cardiac mapping and ablation of arrhythmia.
* Subject agrees to comply with study procedures and be available for routine follow up visits for at least 12 months after enrolment.
* Subject is willing and able to provide written consent
Exclusion Criteria
* Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations.
* Coagulopathy, bleeding diathesis or suspected pro-coagulant state.
* Sepsis, active systemic infection or fever (\>100.5 F/38 C) within a week prior to the ablation procedure.
* Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.
* Renal failure requiring dialysis or renal compromise that in the investigators judgement would increase risk to the subject or deem the subject inappropriate to participate in the study.
* Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used in conjunction with the study or contrast sensitivity that can't be adequately pre-treated prior to the ablation procedure.
* Positive pregnancy test results for female subjects of childbearing or potential or breast feeding.
* Enrolment in a concurrent clinical study that in the judgement of the investigator would increase risk to the subject or deem the subject inappropriate to participate in the study.
* Significant GI bleed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Coventry University
OTHER
University Hospitals Coventry and Warwickshire NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarv Dhanjal, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Coventry and Warwickshire NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Coventry and Warwickshire NHS Trust
Coventry, West Midlands, United Kingdom
University Hospitals Sussex NHS Foundation Trust
Brighton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tarv Dhanjal, PhD
Role: backup
John C Silberbauer, MA MD(Res) FRCP
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TS584122
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.